Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia [3]

AIDS

Volumn 12, Issue 1, 1998, Pages 112-113

  Simonelli, C ^a   Zanussi, S ^a   Comar, M ^a   Vaccher, E ^a   Giacca, M ^a   De Paoli, P ^a   Tirelli, U ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INTERLEUKIN 2; ZIDOVUDINE;

CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIREMIA;

ANTI-HIV AGENTS; ANTIGENS, CD45; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; MALE; PILOT PROJECTS; RNA, VIRAL; VIREMIA; ZIDOVUDINE;

EID: 0031982979     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)